Revvity, Inc. (BIT:1RVTY)
Italy
· Delayed Price · Currency is EUR 82.76
+0.68 (0.83%)
At close: May 2, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 |
| Discovery & Analytical Solutions Product Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Product Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Service Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Service Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Total Discovery & Analytical Solutions Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Total Discovery & Analytical Solutions Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Product Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Product Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Service Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Service Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Total Discovery & Analytical Solutions Revenue (Post-Q2 2022) | 1.25B |
Log In |
Log In |
Log In |
Log In |
| Total Discovery & Analytical Solutions Revenue (Post-Q2 2022) Growth | -2.96% |
Log In |
Log In |
Log In |
Log In |
| Total Diagnostics Revenue (Pre-Q3 2022) | 1.50B |
Log In |
Log In |
Log In |
Log In |
| Total Diagnostics Revenue (Pre-Q3 2022) Growth | 2.92% |
Log In |
Log In |
Log In |
Log In |
| Total Product | 2.34B |
Log In |
Log In |
Log In |
Log In |
| Total Product Growth | -3.22% |
Log In |
Log In |
Log In |
Log In |
| Total Service | 416.82M |
Log In |
Log In |
Log In |
Log In |
| Total Service Growth | 24.54% |
Log In |
Log In |
Log In |
Log In |
| Life Sciences Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Life Sciences Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Applied Markets Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Applied Markets Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 |
| Discovery & Analytical Solutions Operating Income (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Operating Income (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Operating Income (Post-Q2 2022) | 448.02M |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Operating Income (Post-Q2 2022) Growth | -8.45% |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Operating Income (Pre-Q3 2022) | 373.19M |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Operating Income (Pre-Q3 2022) Growth | 16.29% |
Log In |
Log In |
Log In |
Log In |